Current guidelines on the management of European and American dyslipidemias do not agree on their objectives and recommendations
DOI:
https://doi.org/10.19230/jonnpr.4051Keywords:
Cholesterol, triglycerides, dyslipidemia, cardiovascular risk factors, cardiovascular disease, prevention, treatmentAbstract
Prevention of cardiovascular disease (CVD) constitutes a critical priority of daily clinical practice, for both nurses and doctors. In order to achieve this, it’s essential to control dyslipidemia by using guides created by experts, based on available research. Occasionally, however, the amount of scientific research can be so abundant that choosing which studies to include can generate controversy. This study analyzes cases in which guides created in the United States, using evidence from randomized controlled clinical trials, have established a new paradigm compared to European guides, which have considered the designs of the American guides to be observational studies. The fundamental arguments of both sides will be discussed, as well as the resulting controversy and the subsequent reconciliation between both guides, which now place more value on scientific evidence.
Downloads
References
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J. 2016;doi:10.1093/eurheartj/ehw106.
Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Murray CJ, et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation. 2011;29:1483-92.
Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557-67.
Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31-40.
Royo-Bordonada MÁ, Armario P, Lobos Bejarano JM, Pedro-Botet J, Villar Alvarez F, Elosua R, et al. Adaptación española de las guías europeas de 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica. Clin Invest Arterioscler. 2017;29:69-85.
Flores-Mateo G, Grau M, O’Flaherty M, Ramos R, Elosua R, Violan-Fors C, et al. Análisis de la disminución de la mortalidad por enfermedad coronaria en una población mediterránea: España 1998-2005. Rev Esp Cardiol. 2011;64:988-96.
Lahoz C, Mostaza JM. La aterosclerosis como enfermedad sistémica. Rev Esp Cardiol. 2007;60:184-95.
Martínez-González J, Berrozpe M, Badimon L. Historia natural de la arteriosclerosis. Manifestaciones clínicas. Complicaciones agudas y crónicas. Valoración diagnóstica. Medicine. 2001;8:2230-9.
Lorenzo O, Blanco-Colio LM, Martín-Ventura JL, Sánchez-Galán E, Ares-Carrasco S, Zubiri I, et al. Nuevos mediadores implicados en la génesis de la aterosclerosis. Clin Invest Arterioscl. 2009;21:25-33.
Choudhury RP, Fuster V, Fayad ZA. Molecular, celular and functional imaging of atherothrombosis. Nature Reviews. 2004;3:913-25.
Goldstein JL, Brown MS. A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins. Cell. 2015;16:161-72.
Finking G, Hanke H. Nikolaj Nikolajewitsch Anitschkow (1885-1964) established the cholesterol-fed rabbit as a model for atherosclerosis research. Atherosclerosis. 1997;135:1-7.
O’Donnell CJ, Elosua R. Factores de riesgo cardiovascular. Perspectivas derivadas del Framingham Heart Study. Rev Esp Cardiol. 2008;61:299-310.
González-Santos P, Valdivielso P. Diagnóstico clínico y biológico general de las dislipemias aterógenas. En: Merino J, coordinador. Lípidos, arteriosclerosis y riesgo cardiovascular. Unidad 1. Madrid:Drug-Farma;2002.p.31-43.
Badimón L, Vilahur G, Padró T. Lipoproteínas, plaquetas y aterotrombosis. Rev Esp Cardiol. 2009;62:1161-78.
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atheroclerosis Society Consensus Panel. Eur Heart J. 2017; 38:2459-72.
O’Keefe Jr JH, Cordain L, Harris WH, Moe RM, Vogel R. Optimal Low-Densiy Lipoprotein is 50 to 70 mg/dl. Lower is Better and Physiologically Normal. J Am Coll Cardiol. 2004;43:2142-6.
Raymond C, Cho L, Rocco M, Hazen SL. New guidelines for reduction of blood cholesterol: Was it worth the wait? Cleve Clin J. 2014;81:11-9.
Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med. 2008;359:2195-207.
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; DOI:10.1056/NEJMoa1410489.
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
Balcells M. El estudio Framingham. Neurosciences and History. 2016;4:43-6.
Heart Protection Study (HPS). Lancet. 2002;360:7-22.
Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Lancet. 2002;360:1623-30.
Antihypertesive and Lipid-Lowering Treatment to Prevent Heart Attack Trial-Lipid Lowering Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.
Anglo Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Lancet. 2003;361:1149-58.
Pravastatin or Atorvastatin Evaluation and Infection-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI22). N Engl J Med. 2004;350:1495-504.
Grundy SM, Cleeman JI, Merz CNB, Brewer Jr HB, Clark LT, Hunninghake DB, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-39.
ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiologý (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-818.
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635-701.
Stone NJ, Robinson JG, Lichstenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. J Am Coll Cardiol. 2014;63:2889-934.
Martin SS, Blumenthal RS. Conceps and controversies: the 2013 American College of Cardiology/American Heart Association risk assessment and cholesterol treatment guidelines. Ann Intern Med. 2014;160:356-8.
Civeira F, Ascaso J, Masana L. Should we forget about low-density lipoprotein cholesterol? J Am Coll Cardiol. 2014;63:1228-9.
Lobos JM, Galve E, Royo-Bordonada MA, Alegría E, Armario P, Brotons C, et al. Posicionamiento del Comité Español Interdisciplinario de Prevención Cardiovascular y la Sociedad Española de Cardiología en el tratamiento de las dislipemias. Divergencia entre las guías europea y estadounidense. Rev Esp Cardiol. 2014;67:913-9.
Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37:2999-3058.
Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly Jr DD, DePalma SM, et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents Endorsed by the National Lipid Association. J Am Coll Cardiol. 2016;68:92-125.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-88.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1046-e1081.
Raygor V, Khera A. New Recommendations and Revised Concepts in Recent Guidelines on the Management of Dyslipidemias to Prevent Cardiovascular Disease: the 2018 ACC/AHA and 2019 ESC/EAS Guidelines. Curr Cardiol Rep. 2020;22:87. doi: 10.1007/s11886-020-01331-z.
Watts GF, Gidding SS, Mata P, Pang J, Sullivan DR, Yamashita S, et al. Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care. Nat Rev Cardiol. 2020;17:360-77.
Pérez de Isla L, Arroyo-Olivares R, Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, et al. SAFEHEART researchers. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry. Rev Esp Cardiol (Engl Ed). 2020;73:828-34.
Ellis KL, Pérez de Isla L, Alonso R, Fuentes F, Watts GF, Mata P. Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia. J Am Coll Cardiol. 2019;73:1029-39.
Pérez de Isla L, Alonso R, Mata N, Fernández-Pérez C, Muñiz O, Díaz-Díaz JL, et al. Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017;135:2133-44.
Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. A Global Call to Action. Representatives of the Global Familial Hypercholesterolemia Community JAMA Cardiol. 2020;5:217-29.
Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias. SEC Working Group for the 2019 ESC/EAS guidelines for the management of dyslipidaemias, Expert Reviewers for the 2019 ESC guidelines for the management of dyslipidaemias, SEC Guidelines Committe. Rev Esp Cardiol. 2020;73:348–53.
Carbayo Herencia JA, Simarro Rueda M, Palazón Bru A, Molina Escribano F, Ponce García I, Artigao Ródenas LM, et al; Todos en nombre del Grupo de Enfermedades Vasculares de Albacete (GEVA). Evaluation of non-HDL cholesterol as a predictor of non-fatal cardiovascular events in a prospective population cohort. Clin Investig Arterioscler. 2018;30:64-71.
SEC Working Group for the 2019 ESC/EAS guidelines for the management of dyslipidaemias, Expert Reviewers for the 2019 ESC guidelines for the management of dyslipidaemias, SEC Guidelines Committe. Comments on the 2019 ESC/EAS guidelines for the management of dyslipidemias. Rev Esp Cardiol (Engl Ed). 2020;73:348-353.
Brotons C, Esteban M, García Lerín A, Lekuona I, Pintó X, Rodríguez Padial L, et al. Homogeneización de los valores del perfil lipídico. Documento de consenso. Barcelona: Sociedad Española de Medicina del Laboratorio; 2017.
Escobar C, Anguita M, Arrarte V, Barrios V, Cequier Á, Cosín-Sales J, et al. Expert reviewers. Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology. Rev Esp Cardiol (Engl Ed). 2020;73:161-167.
Lago Deibe F, Escribano D, Párraga I. Guía de dislipemias SEC_SEA 2019. Comentarios desde la perspectiva del médico de familia. Barcelona: Sociedad Española de Medicina de Familia y Comunitaria; 2020.
Pérez-Jiménez F, Pascual V, Meco JF, Pérez Martínez P, Delgado Lista J, Domenech M, et al. Document of recommendations of the SEA 2018. Lifestyle in cardiovascular prevention. Clin Investig Arterioscler. 2018;30:280-310.
Piepoli MF, Abreu A, Albus C, Ambrosetti M, Brotons C, Catapano AL, et al. Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. Eur J Prev Cardiol. 2020;27:181–205.
Armario P, Brotons C, Elosua R, Alonso de Leciñana M, Castro A, Clarà A, et al. Comentario del CEIPV a la actualización de las Guías Europeas de Prevención Vascular en la Práctica Clínica. Rev Esp Salud Pública. 2020;94:e1-38.
Mostaza JM, Pintó X, Armario P, Masana L, Ascaso JF, Valdivielso P; en nombre de la Sociedad Española de Arteriosclerosis; Miembros de la Sociedad Española de Arteriosclerosis. Standards for global cardiovascular risk management arteriosclerosis. Clin Investig Arterioscler. 2019;31 Suppl 1:1-43.
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
